PureTech’s PRTC reports positive Phase 1 GlyphAllo topline results
PureTech Health plc says Seaport Therapeutics has reported positive topline Phase 1 results from a GlyphAllo simulation trial in healthy volunteers.
PureTech Health plc said its founded entity, Seaport Therapeutics, reported positive topline results from a Phase 1 driving simulation trial of GlyphAllo™ in healthy volunteers. The release is dated 09 September 2026 and 9 September 2026.